Clinical trials: copd or chronic obstructive
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.
- Trial name
- COPD (NCT02459080)
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 619 people
- Sponsor
- Mylan Inc.
Pulmonary Hypertension
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
The primary objectives of this study are to assess the safety/tolerability and efficacy (by evaluating changes in pulmonary vascular resistance [PVR] and pulmonary blood volume [PBV]) of frespaciguat in participants with…
- Trial name
- NCT04370873
- Testing
- Frespaciguat
- Where
- 9 sites in United States, Israel and 1 more
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Pulmonary Disease
HomeVent ( Connect) Registry: EU COPD Home NIV Registry
The prevalence of chronic respiratory disease, including chronic obstructive pulmonary disease (COPD), is increasing in industrialized countries.
- Trial name
- HOmeVent (NCT02811588)
- Testing
- Non-invasive ventilation
- Where
- 4 sites in Germany
- Volunteers
- 169 people
- Sponsor
- ResMed
Pulmonary Disease, Chronic Obstructive
Ipratropium or Salbutamol Sulphate Alone or Combination Therapy Salbutamol and Ipratropium in Patients With COPD
Study to compare the effects of nebulised salbutamol or ipratropium alone in patients with COPD with those of combined salbutamol and ipratropium nebuliser solution on arterial oxygen saturation (SaO2) and to characterise…
- Trial name
- NCT02182856
- Testing
- Ipratropium bromide 500 µg/salbutamol sulphate 3 mg, Ipratropium 500 µg, Salbutamol sulphate 3 mg
- Volunteers
- 33 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD
Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017
The primary objective of the study is to characterize the safety profile and duration of bronchodilation of a single dose of inhaled TV46017
- Trial name
- NCT02315131
- Testing
- TV46017
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Bronchitis
RejuvenAir® System Trial for COPD With Chronic Bronchitis
Chronic Obstructive Pulmonary Disease (COPD) is defined as an impaired ability to move air within the lungs and is a major public health problem that is projected to rank fifth worldwide in terms of disease burden and third in…
- Trial name
- SPRAY-CB (NCT03893370)
- Testing
- RejuvenAir System
- Where
- 27 sites in United States, United Kingdom
- Volunteers
- 210 people
- Sponsor
- CSA Medical, Inc.
Pulmonary Disease, Chronic Obstructive
Special Survey Long-term Treatment With Tiotropium on COPD
Since Spiriva Inhalation Capsules 18mcg (hereinafter this product) are indicated for treatment of patients with chronic obstructive pulmonary disease (i.e.
- Trial name
- NCT00638183
- Where
- 89 sites in Japan
- Volunteers
- 385 people
- Sponsor
- Boehringer Ingelheim
Chronic Bronchitis
Gala FIH Feasibility Study for the Treatment of Chronic Bronchitis
Feasibility trial (FIH) to assess the safety and clinical utility in patients with chronic bronchitis.
- Trial name
- NCT03107494
- Testing
- Gala Airway Treatment System
- Where
- 2 sites in Austria, Chile
- Volunteers
- 18 people
- Sponsor
- Gala Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
CareCOPD - COPD Home Monitoring Study
This is a pilot study to demonstrate early validation of objective home-monitoring of Chronic obstructive pulmonary disease (COPD) patients by combining accurate and relevant patient data of medication and lung function (lung…
- Trial name
- NCT04918095
- Testing
- CareCOPD Platform
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cognita Labs LLC
Healthy
A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer
The primary purpose of this study is to demonstrate the equivalence of budesonide, glycopyrronium, formoterol (BGF) metered dose inhaler (MDI) hydrofluoroolefin (HFO) with a spacer to BGF MDI hydrofluoroalkane (HFA) with a…
- Trial name
- NCT06340581
- Testing
- Treatment A: BGF MDI HFA, Treatment B: BGF MDI HFO, Treatment C: BGF MDI HFO
- Volunteers
- healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
RELOVAIR® Lung Deflation Study
The primary objective of the study is to test the hypothesis that lung hyperinflation contributes to cardiac dysfunction in COPD and that the treatment of lung deflation with FF/VI Inhalation Powder 100/25 mcg administered once…
- Trial name
- NCT01691885
- Testing
- Fluticasone Furoate, Vilanterol
- Where
- United Kingdom
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010
Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010
- Trial name
- NCT03311373
- Testing
- Regimen A, Regimen B, Regimen C
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Pearl Therapeutics, Inc.
Breathlessness, COPD
Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers
The Sentinel-001 study aims to identify a combination of biomarkers suitable for triage of breathlessness.
- Conditions
- Breathlessness, COPD, Asthma, Asthma Chronic
- Trial name
- NCT05304494
- Testing
- Biomarker tests for participant profiling
- Sponsor
- Sanome
COPD (Chronic Obstructive Pulmonary Disease)
A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a common, progressive, and heterogeneous respiratory disorder. It is associated with substantial morbidity and mortality worldwide, leading to progressive decline in lung function…
- Trial name
- NCT07828353
- Testing
- REGEND001
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Regend Therapeutics
Emphysema
Exhale (R) Stent for Emphysema
Current treatment for emphysema is limited to measures that include inhaled oxygen, bronchodilators, anti-inflammatory drugs and pulmonary rehabilitation.
- Trial name
- NCT00207337
- Testing
- Exhale Drug-Eluting Stent
- Where
- 6 sites in Australia, Brazil and 1 more
- Volunteers
- 60 people
- Sponsor
- Broncus Technologies
Chronic Graft Versus Host Disease
Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)
The primary objective of this study is to evaluate the effect of entospletinib (ENTO) on the best overall response rate in adults with chronic graft versus host disease (cGVHD) who are currently receiving systemic corticosteroids…
- Trial name
- NCT02701634
- Testing
- ENTO
- Where
- 30 sites in United States, Canada and 5 more
- Volunteers
- 66 people
- Sponsor
- Gilead Sciences
Pulmonary Disease, Chronic Obstructive
Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example
Documentation of successful therapy with tiotropium (Spiriva Respimat; Spiriva (tiotropium 18 mcg capsules)) in COPD patients requiring long-acting bronchodilators: description of the most important outcome parameters according…
- Trial name
- NCT01036763
- Where
- 352 sites in Germany
- Sponsor
- Boehringer Ingelheim
COPD
To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to assess and compare the pharmacokinetics (PK) of Tiotropium delivered via Breath Actuated Inhaler (BAI) (4.5 mcg/day or 9.0 mcg/day), SPIRIVA®, HandiHaler®, (18 mcg/day) and Respimat® Soft…
- Trial name
- NCT01785433
- Testing
- Tiotropium HFA BAI 4.5 mcg, Tiotropium HFA BAI 9.0 mcg, SPIRIVA® HandiHaler® 18 mcg/day
- Where
- 5 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
COPD
Non-interventional Study of Spirometry Use to Diagnose COPD (Chronic Obstructive Pulmonary Disease) and to Prescribe Treatment to COPD Patients in the Outpatient Institutions
This study is an observational multicenter descriptive study. The study will be conducted in primary outpatient medical institutions in different cities of the RF.
- Trial name
- SUPPORT (NCT02248909)
- Where
- 22 sites in Russia
- Volunteers
- 4,232 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, Chronic Obstructive Pulmonary Disease (COPD)
A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)
The purpose of this study is to assess the safety of GW856553 in COPD patients and to assess its affects on their COPD disease after 14 days.
- Trial name
- NCT00392587
- Testing
- GW856553
- Where
- 3 sites in Germany
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline